Search clinical trials for: Glucophage XR (Comparator drug)

Total 2309 results

Merck Sharp & Dohme LLC

Completed

A Study of the Safety and Efficacy of Omarigliptin (MK-3102) in ≥18 and <45 Year-Old Participants With Type 2 Diabetes Mellitus and Inadequate Glycemic Control (MK-3102-028)

Diabetes Mellitus
Mylan Pharmaceuticals Inc

Completed

Food Study Metformin Hydrochloride ER Tablets 750 mg and Glucophage XR 750 mg

Healthy

United States
University of Massachusetts, Worcester

Not yet recruiting

Preventing T2DM After GDM With Immediate Postpartum Screening and Treatment

Type 2 Diabetes | Gestational Diabetes

United States
Mylan Pharmaceuticals Inc

Completed

Food Study Metformin Hydrochloride ER Tablets 500 mg and Glucophage® XR 500 mg

Healthy

United States
Teva Pharmaceuticals USA

Completed

Metformin ER 750 mg Tablets, Fed

Healthy

Canada
Teva Pharmaceuticals USA

Completed

Metformin ER 750 mg Tablets, Fasting

Healthy

Canada
Allergan

Completed

Safety and Tolerability of Trospium Chloride and Metformin Hydrochloride in Healthy Subjects

Healthy

United States
Mylan Pharmaceuticals Inc

Completed

Fasting BE Study of Metformin Hydrochloride ER Tablets 500 mg and Glucophage® XR Tablets 500 mg

Healthy

United States
Pauls Stradins Clinical University Hospital

Completed

Coronary Artery Disease Progression in Patients With Prediabetes

Coronary Artery Disease | Atherosclerosis | Prediabetic State

Latvia
Mylan Pharmaceuticals Inc

Completed

Fasting Study of Metformin Hydrochloride ER Tablets 750 mg and Glucophage® XR Tablets 750 mg

Healthy

United States
Mylan Pharmaceuticals Inc

Completed

Fasting Study of Metformin Hydrochloride ER Tablets 500 mg and Glucophage® XR Tablets 500 mg

Healthy

United States
Celon Pharma SA
National Center for Research and Development, Poland

Completed

Safety and Pharmacokinetics Study of CPL207280 Compound in Healthy Volunteers.

Healthy Volunteers

Poland
Mayo Clinic
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Daiichi... and other collaborators

Completed

The Effect of Welchol on Glucose Metabolism in Type 2 Diabetics

Type 2 Diabetes

United States
AstraZeneca

Completed

Bioequivalence Study of the Fixed Dose Combination of 5 mg Saxagliptin and 500 mg Metformin XR Tablet (Manufactured in Mt Vernon, IN) Relative to 5 mg Saxagliptin Tablet and 500 mg Metformin XR Tablet (Manufactured in Evansville, IN)

Diabetes Mellitus

United States
AstraZeneca

Withdrawn

BE Study of the Fixed Dose Combination of 5 mg Saxagliptin and 500 mg Metformin HCl XR Tablet Relative to a 5 mg Saxagliptin (Onglyza™) Tablet and a 500 mg Metformin HCl XR (Glifage® XR Marketed in Brazil by Merck S.A.) Tablet Co-Administered to Healthy Subjects in the Fasted and Fed States

Type 2 Diabetes

Brazil
Astellas Pharma Europe B.V.

Completed

A Study to Assess the Efficacy and Safety of Ipragliflozin in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin (IMPRESSION)

Type 2 Diabetes Mellitus

Russian Federation
Merck Sharp & Dohme LLC

Completed

Addition of Omarigliptin (MK-3102) to Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Combination Therapy With Glimepiride and Metformin (MK-3102-022)

Type 2 Diabetes Mellitus
IPCA Laboratories Ltd.

Completed

Bioequivalence Study of Metformin Hydrochloride Extended-Release Tablets USP 750 mg Under Fasting Condition

Fasting

India
Cook County Health
Bristol-Myers Squibb

Completed

Outpatient Discharge Therapy With Saxagliptin+MetforminXR vs GlipizideXL for Type 2 Diabetes With Severe Hyperglycemia

Hyperglycemia | Diabetes Mellitus Type 2

United States
AstraZeneca

Completed

Study To Evaluate 24 Hour Blood Sugar Control (24-hour Mean Weighted Glucose) In Subjects That Are Taking Saxagliptin 5 mg Added Onto Metformin XR 1500 XR mg Compared To Subjects Taking Metformin XR 1500 mg Up-titrated To Metformin XR 2000 mg

Type 2 Diabetes

United States, Argentina, Mexico, Israel
IPCA Laboratories Ltd.

Completed

Bioequivalence Study of Metformin Hydrochloride Extended-Release Tablets USP 750 mg Under Fed Condition

Fasting

India
Chong Kun Dang Pharmaceutical

Completed

A Clinical Study to Compare the Pharmacokinetic Characteristics of CKD-395 0.5/1000 mg in Healthy Male Volunteers

Diabetes Mellitus, Type II

Korea, Republic of
Actavis Inc.

Completed

A Relative Bioavailability Study of Metformin HCl 750 mg ER Tablets Under Fasting Conditions

Healthy

United States
Actavis Inc.

Completed

A Relative Bioavailability Study of Metformin HCl 750 mg ER Tablets Under Non-fasting Conditions

Healthy

United States
Actavis Inc.

Completed

A Relative Bioavailability Study of Metformin HCl 500 mg ER Tablets Under Fasting Conditions

Healthy

United States
Sandoz

Completed

To Demonstrate the Relative Bioavailability of Metformin HCL 500 mg Extended Release (XR) Tablets Under Fasting Conditions

Type II Diabetes
Actavis Inc.

Completed

A Relative Bioavailability Study of Metformin HCl 500 mg ER Tablets Under Fasting Conditions

Healthy

United States
ARKAY Therapeutics
Albany Medical College

Not yet recruiting

Evaluation of Superiority of Valsartan+Celecoxib+Metformin Over Metformin Alone in Type 2 Diabetes Patients (RESILIENCE)

Obesity | Arthritis | Type 2 Diabetes | High Blood Pressure

United States
Actavis Inc.

Completed

A Relative Bioavailability Study of Metformin HCl 500 mg ER Tablets Under Non-fasting Conditions

Healthy

United States
Merck Sharp & Dohme LLC

Completed

A Study to Assess the Safety and Efficacy of Omarigliptin (MK-3102) in Participants With Type 2 Diabetes Mellitus (T2DM) and Inadequate Glycemic Control (MK-3102-011)

Type 2 Diabetes Mellitus
AstraZeneca

Completed

Bioequivalence Study of the Fixed Dose Combination of 5 mg Saxagliptin/1000 mg Metformin XR (Manufactured in Mt Vernon, IN) Relative to 5 mg of Onglyza and 2 × 500 mg Glucophage XR

Diabetes Mellitus

United States
UCB Pharma

Completed

Long Term Follow-up Study With Keppra XR (Levetiracetam XR) for Partial Seizures

Epilepsy

United States, Poland, Mexico, Russian Federation
Joint Stock Company "Farmak"

Completed

Fasting Bioequivalence Study of 2 Metformin 500 mg Prolonged Release Tablets in 44 Healthy Male and Female Volunteers

Pharmacokinetics

Czechia
Dan Zandberg

Recruiting

Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies

Melanoma | Hepatocellular Carcinoma | NSCLC | Gastric Adenocarcinoma | Esophageal Adenocarcinoma | Urothelial Cancer | HNSCC | Microsatellite Instability-High Solid Malignant Tumor

United States
AstraZeneca
Biocard

Completed

An Open-label, Randomized, Crossover Study of Comparative Pharmacokinetics and Bioequivalence of Dapagliflozin + Metformin, 10 mg + 1000 mg Versus the Combined Use of Forxiga™, 10 mg and Two Glucophage® Long, ER Tablets, 500 mg Co-administered to Healthy Volunteers Under Standard Fed Conditions

Diabetes Mellitus, Type 2

Russian Federation
Boehringer Ingelheim

Completed

Bioequivalence Study of Two Strengths of Two Different Metformin Tablets Administered to Healthy Male and Female Subjects

Healthy
Envisia Therapeutics

Completed

Safety and Efficacy of ENV515 Travoprost Extended Release (XR) in Patients With Bilateral Ocular Hypertension or Primary Open Angle Glaucoma

Glaucoma and Ocular Hypertension

United States
Merck Sharp & Dohme LLC

Completed

Monotherapy Study in Patients With Type 2 Diabetes Mellitus (0431-021)

Diabetes Mellitus, Type 2
Trisha Wise-Draper
American Cancer Society, Inc.

Active, not recruiting

Combining Pembrolizumab and Metformin in Metastatic Head and Neck Cancer Patients

Head and Neck Squamous Cell Carcinoma

United States
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Safety, Tolerability, and Efficacy of the Addition of Omarigliptin (MK-3102) to Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Therapy (MK-3102-024)

Type 2 Diabetes Mellitus
PegBio Co., Ltd.
Covance

Completed

Dose-finding of PB-119 Administered Subcutaneously Once Weekly Versus Placebo in Subjects With Type 2 Diabetes

Type 2 Diabetes Mellitus (T2DM)

United States
AstraZeneca

Completed

Bioequivalence Study of Combination Tablets of Saxagliptin / Dapagliflozin / Metformin XR (Extended-release) and Dapagliflozin / Metformin XR Relative to Individual Components in Healthy Subjects

Type 2 Diabetes Mellitus

United Kingdom
Merck Sharp & Dohme LLC

Completed

A Study to Demonstrate the Bioequivalence of Sitagliptin/Metformin Combination Tablets and Co-administration of Sitagliptin and Metformin as Individual Tablets (0431A-095)

Type 2 Diabetes
UCB BIOSCIENCES, Inc.

Completed

Study Evaluating the Pharmacokinetics of Keppra Extended Release (XR) in Children and Adults With Epilepsy

Epilepsy

United States
Takeda

Completed

Efficacy and Safety of Alogliptin Plus Metformin in Patients With Type 2 Diabetes (AM7D)

Diabetes Mellitus, Type 2

United States, Ukraine, Israel, Mexico, Romania, Russian Federation, South Africa, Czech Republic, Puerto Rico, Poland, Hungary, Lithuania, Slovakia
Dexa Medica Group

Completed

Efficacy and Safety of DLBS3233 in Subjects With Polycystic Ovary Syndrome (PCOS)

Polycystic Ovary Syndrome (PCOS)

Indonesia
Dr. Reddy's Laboratories Limited

Completed

Bioequivalence Study of Metformin Hydrochloride Tablets 1000 mg Tablets of Dr. Reddy's Laboratories Limited Under Fasting Condition

Healthy

India
Dr. Reddy's Laboratories Limited

Completed

Bioequivalence Study of Metformin Hydrochloride Tablets 1000 mg Tablets of Dr. Reddy's Laboratories Limited Under Fed Condition

Healthy

India
University Hospitals Cleveland Medical Center
National Alliance for Research on Schizophrenia and Depression; AstraZeneca

Completed

Quetiapine Extended Release (XR) in Bipolar Patients With Comorbid Generalized Anxiety Disorder (GAD)

Anxiety Disorders | Anxiety | Bipolar Disorder | Substance Use Disorders

United States
Merck Sharp & Dohme LLC

Completed

A Study to Test the Safety and Efficacy of Adding Sitagliptin in Patients With Type 2 Diabetes Mellitus (MK0431-074)

Type 2 Diabetes Mellitus

3

Subscribe